Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
© 2026 Forbes Digital Marketing Inc (FDMI). Forbes Advisor is operated by FDMI and is not controlled by Forbes Media LLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results